Azanonaboranes [(RNH(2))B(8)H(11)NHR] as possible new compounds for use in boron neutron capture therapy.
The synthesis and biological in vitro and in vivo activities of possible new compounds for Boron Neutron Capture Therapy (BNCT) are reported. The azanonaboranes of the type [(RNH(2))B(8)H(11)NHR] are water-soluble when hydrophilic groups are introduced. The reaction of B(9)H(13)SMe(2) with primary amines yields azanonaboranes. Five compounds with different numbers of hydroxypropyl groups have been isolated: [(HO(CH(2))(3)NH(2))B(8)H(11)NHCH(3)] (4), [(HO(CH(2))(3)NH(2))B(8)H(11)NH(CH(2))(3)OH] (2), [((HO(CH(2))(3))(2)NH)B(8)H(11)NHCH(3)] (6), [((HO(CH(2))(3))(2)NH)B(8)H(11)NH(CH(2))(3)OCH(3)] (11) and [((HO(CH(2))(3))(2)NH)B(8)H(11)NH(CH(2))(3)OH] (8). In vitro experiments as judged by cloning survival tests showed that two of the synthesised compounds are not toxic. The in vivo experiments were carried out with C3H/He mice bearing SCCVII tumours and C57 mice bearing B16 tumours. Compounds 2 and 6 have no particular affinity to any tissue, but are excluded from the brain.